"The Once A Day Protease Inhibitor Regimens"
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1 infected people, Antiretroviral treatment-naïve, Atazanavir, Fosamprenavir, ARV Treatment Naive
Eligibility Criteria
Inclusion Criteria: 18 years of age or older. Patient agrees to participate in the study by giving written informed consent. Documentation of HIV infection. No prior treatment with any anti-retroviral agent. CD4 cell count < 350 cells x mm3 or with an AIDS defining condition. Viral load > 1,000 copies/mL Exclusion Criteria: Less than 18 years old. Current pregnancy or breastfeeding. Any previous antiretroviral regimen. Severe hepatic impairment that precludes the use of either study drug. This will be defined as any laboratory value of Grade 3 or 4 on the ACTG scale. Use of any contra-indicated medication as defined in the package insert for each drug. Any condition that, in the judgment of the investigator, precludes successful participation in the study.
Sites / Locations
- Thomas Street Health Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Atazanavir oral once daily
Fosamprenavir oral once daily
HIV treatment
HIV treatment